Last reviewed · How we verify
NCT06554574
A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants
Phase 1 trial testing LTG-305 in Healthy in 112 participants. Completed in 16 June 2025.
16 June 2025
Quick facts
| Lead sponsor | Latigo Biotherapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 112 |
| Start date | 3 September 2024 |
| Primary completion | 16 June 2025 |
| Estimated completion | 16 June 2025 |
| Sites | 1 location across New Zealand |
Drugs / interventions tested
- LTG-305 — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Latigo Biotherapeutics — full company profile →
Who can join
Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) and Pharmacodynamics of orally administered LTG-305 in healthy male and female participants. The study will also include a randomized, double-blind, placebo-controlled within-participant crossover evaluation of pain tolerance during a cold pressor test in healthy male participants 18-55 years of age.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Voltage-gated sodium channels in excitable cells as drug targets.
Alsaloum M, Dib-Hajj SD, Page DA, Ruben PC, et al · · 2025 · cited 37× · PMID 39901031 · DOI 10.1038/s41573-024-01108-x -
Recent advances in the pharmacology of voltage-gated ion channels.
Lopez-Mateos D, Harris BJ, Hernández-González A, Yarov-Yarovoy V, et al · · 2025 · cited 4× · PMID 41092810 · DOI 10.1016/j.pharmr.2025.100090 -
Voltage-gated sodium channels in the nervous system: Molecular physiology to therapeutic interventions.
Li N, Yan L, Peng A, Fu X, et al · · 2026 · PMID 40808385 · DOI 10.4103/nrr.nrr-d-25-00260
Verify or expand the search:
- PubMed search for NCT06554574
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Latigo Biotherapeutics trials
Trials by the same sponsor.
- NCT07341152 — A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants · Phase 1 · completed
- NCT07102459 — An Efficacy and Safety Study of LTG-001 Following Abdominoplasty · Phase 2 · completed
- NCT06972212 — Pharmacodynamic Study of 100mg Suzegtrigine vs Placebo in Healthy Male Adults · EARLY_PHASE1 · completed
- NCT06774625 — This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Mo · Phase 2 · completed
- NCT06600607 — Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adults · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06554574 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Latigo Biotherapeutics
- Last refreshed: 4 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06554574.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing